Evidence map›Paper›PMID 32390424›Full record

ArticleJournal of medicinal chemistry2020

Discovery of the First Vitamin K Analogue as a Potential Treatment of Pharmacoresistant Seizures.

Xiaoyang Li, Richard A Himes, Lyndsey C Prosser, Charleston F Christie, Emma Watt, Sharon F Edwards, Cameron S Metcalf, Peter J West, Karen S Wilcox, Sherine S L Chan and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. An assessment of vaping-induced inflammation and toxicity: A feasibility study using a 2-stage zebrafish and mouse platform.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2022
    Article
  10. Menadione: a platform and a target to valuable compounds synthesis.Beilstein journal of organic chemistry · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Xiaoyang LiSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266071, China.ORCID 0000-0003-3684-2106
Richard A HimesDepartment of Chemistry and Biochemistry, College of Charleston, 66 George Street, Charleston, South Carolina 29424, United States.
Lyndsey C ProsserDepartment of Chemistry and Biochemistry, College of Charleston, 66 George Street, Charleston, South Carolina 29424, United States.
Charleston F ChristieNeuroene Therapeutics, Mount Pleasant, South Carolina 29464, United States.
Emma WattDepartment of Chemistry and Biochemistry, College of Charleston, 66 George Street, Charleston, South Carolina 29424, United States.
Sharon F EdwardsAnticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84112, United States.
Cameron S MetcalfAnticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84112, United States.
Peter J WestAnticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84112, United States.
Karen S WilcoxAnticonvulsant Drug Development (ADD) Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84112, United States.
Sherine S L ChanNeuroene Therapeutics, Mount Pleasant, South Carolina 29464, United States.
C James ChouNeuroene Therapeutics, Mount Pleasant, South Carolina 29464, United States.ORCID 0000-0001-6808-9089
University of Utah · USCollege of Charleston · USMedical University of South Carolina · USOcean University of China · CN

Funding

Development of new anti-epilepsy treatments targeting cellular energetics through mitochondrial modulation with optimal pharmacokinetics and toxicity profilesR44NS097047 · NINDS · NEUROENE THERAPEUTICS INC · PI CHAN, SHERINE S, HIMES, RICHARD A · 2018 to 2019
$1.6M
Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapiesR41NS097047 · NINDS · NEUROENE THERAPEUTICS INC · PI CHAN, SHERINE S · 2016 to 2016
$225k
NINDS NIH HHS R41 NS097047NINDS NIH HHS R44 NS097047
6 · The paper itself

Abstract

Despite the availability of more than 25 antiseizure drugs on the market, approximately 30% of patients with epilepsy still suffer from seizures. Thus, the epilepsy therapy market has a great need for a breakthrough drug that will aid pharmacoresistant patients. In our previous study, we discovered a vitamin K analogue,

Indexed as

Administration, OralAnimalsAnticonvulsantsBrainCell Line, TumorCell SurvivalCytochrome P-450 Enzyme SystemDisease Models, AnimalDrug Evaluation, PreclinicalHalf-LifeHumansIsoenzymesMaleMiceSeizuresStructure-Activity RelationshipAnticonvulsantsCytochrome P-450 Enzyme SystemIsoenzymesVitamin K

Identifiers

PMID32390424
PMCPMC7684765
OpenAlexW3022418367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.